RecruitingNCT06913712

BMI in Idiopathic Intracranial Hypertension and Its Relationship With the Response to Treatment

Evolution of Body Mass Index in Idiopathic Intracranial Hypertension and Its Relationship With the Response to Treatment. Retrospective and Prospective Study

Sponsor

University of Valencia

Enrollment

25 participants

Start Date

Jun 27, 2024

Study Type

OBSERVATIONAL

Conditions

Idiopathic Intracranial Hypertension (IIH)

Summary

1. To establish the correlation between the evolution of the body mass index in benign intracranial hypertension and the response to treatments. 2. To establish the BMI at which this disease occurs. 3. To establish how much the BMI must be reduced to cure this disease. 4. To assess the evolution and response to treatments of sick people who DO NOT reduce or even continue to increase their BMI despite treatment with Acetazolamide or a possible CSF diversion

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is examining the relationship between body weight (BMI) and a condition called idiopathic intracranial hypertension (IIH) — where the pressure around the brain is too high without a clear cause — and how BMI affects treatment outcomes. **You may be eligible if...** - You are 18 or older - You have been diagnosed with idiopathic intracranial hypertension (IIH) according to established diagnostic criteria (Dandy criteria) - Other causes of raised brain pressure have been ruled out **You may NOT be eligible if...** - Your headaches or increased brain pressure are caused by something else (such as tension-type headache, Chiari malformation, or another condition) - You have a secondary cause for raised brain pressure such as a brain abnormality, blood clot, or a medication side effect Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERWeight loss without pharmacotherapy

The study will record the weight of the patients with Idiopathic Intracranial Hypertension every three months. It will correlate with the response to the different treatment modalities (weight loss with no other intervention, diuretic drugs (acetazolamide), lumboperitoneal shunt, or ventriculoperitoneal shunt). No medication will be provided to help lose weight.